Bionomics (ASX:BNO, BNOOA, BNOOB, US OTC:BMICY) today announced that it has been granted a patent in New Zealand for a series of compounds that have shown promise as potential new treatments for cancer.
CellSpray R is intended for use in patients with between 30-90% injuries to the body. CellSpray R was launched in September at the European Burns Association meeting in Portugal, which was attended by leading surgeons from throughout Europe.
Australian biotechnology company Peptech Limited (ASX: PTD) today announced its joint venture partner Biosceptre International Limited had been granted a patent in Australia related to the diagnostic use of antibodies binding to a cancer cell marker.
